



ASX ANNOUNCEMENT

7 December 2023

Completion of Entitlement Offer

On 25 October 2023, Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric** or **Company**) announced the details of a non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$10 million. Under the Entitlement Offer, eligible shareholders were able to subscribe for 2 new fully paid ordinary shares in Chimeric (**New Shares**) for every 3 fully paid ordinary shares in Chimeric at the issue price of \$0.028 per New Share.

On 15 November 2023, Chimeric extended the closing date of the Entitlement Offer to 5pm (AEDT) on 30 November 2023. Chimeric received valid applications under the Entitlement Offer for 159,399,542 New Shares, raising an amount of approximately \$4.5 million.

Chimeric's Managing Director Ms Jenn Chow said "we are pleased with the strong support shown by shareholders in our recent rights issue. This additional funding provides us with further runway to continue our programs and is additional to the focus on strict cost controls and cash management we have put in place during 2023."

Issue and allotment of the New Shares will occur today, and ASX trading of the New Shares is expected to commence on 8 December 2023.

A shortfall of approximately 196,735,762 New Shares (representing an amount of approximately \$5.5 million) remains. As the Entitlement Offer is not underwritten, the shortfall has not been issued and may be placed by the Company in accordance with the ASX listing rules.

The Directors thank all eligible shareholders who participated in the Entitlement Offer for their continuing support.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).



This announcement has been authorised by the Board of Chimeric.

Phillip Hains
Company Secretary

Important information

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Chimeric does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.